San Diego, CA-based Tang Capital Management, founded in 2002 by Kevin C. Tang is a hedge fund that specializes in the life sciences industry. Prior to founding his firm, Mr. Tang was most recently the Managing Director and head of Life Sciences research group at Deutsche Banc Alex Brown. As of the most recent filing for the March 2012 quarter, filed with the SEC last week, it held $429 million in 13-F assets. Between firm inception and through May, 2010, the firm had generated a total return of 520%, or 26% on an annualized basis, compared to the 5.3% average annual return for the S&P 500 over the same period.
Kevin Tang is currently invested in 4 companies run by Chris Henney including, Dendreon, Cytacal, Onty and Anth. With Tang's move last week to double his investment in Anth, he is clearly expecting something positive.
Great management, strong data, trading at cash levels make ANTH a pretty interesting value play at this point. We'll see.
"strong data"? When it was released, the stock went from 3 dollars to 60 cents...Are you delusional? Imagine if it was "really, really strong data", the stock would be at 15 cents in your little world. I mean, buy the stock because of cash, etc., but please don't say the data was strong. A total of 17 patients had some form of improvement over placebo. 17. With the ebb and flow of lupus symptoms, this could merely be the result of luck. And that is why a phase III is necessary... Or the FDA would have just approved the drug!